癌症特异性健康经济学测量工具QLU-C10D在甲状腺癌患者健康效用评估中的有效性与反应性
这项多中心、多国前瞻性队列研究纳入9个国家181例分化型、髓样型或未分化型甲状腺癌患者,纵向采集EORTC QLQ-C30与EQ-5D-5L数据,用7套国家价值集推导效用值,并以EQ-5D-5L为对照偏好性测量工具。结果显示QLU-C10D无地板或天花板效应,跨测量时点组内相关系数为0.761至0.901,支持效标效度;在15项已知组比较中检出9项差异,所有国家价值集均检出临床重要变化,支持反应性。作者认为QLU-C10D是甲状腺癌研究中健康经济评价的有效偏好性测量工具,并推荐用于甲状腺癌治疗经济评价中的健康效用估计。
要点
- QLU-C10D在181例甲状腺癌患者中与EQ-5D-5L的组内相关系数为0.761至0.901,支持效标效度。
- QLU-C10D无地板或天花板效应,在15项已知组比较中检出9项差异,支持敏感性。
- 所有QLU-C10D国家价值集均检出临床重要变化,支持反应性。
核心结论
- QLU-C10D是甲状腺癌研究中健康经济评价的有效偏好性测量工具,作者推荐将其用于甲状腺癌治疗经济评价中的健康效用估计。
研究设计与样本
- 多中心、多国前瞻性队列研究,纵向采集甲状腺癌患者的EORTC QLQ-C30与EQ-5D-5L数据。
- 共纳入来自9个国家(3个大洲)的181例甲状腺癌患者,纳入分化型、髓样型或未分化型甲状腺癌患者。
- 应用7套国家特定价值集从QLQ-C30数据推导国家特定效用值,并以EQ-5D-5L作为对照偏好性测量工具。
主要发现
- 两种工具的平均效用值总体低于一般人群常模。
- QLU-C10D不存在地板或天花板效应。
- EQ-5D-5L与QLU-C10D指数值的组内相关系数在各测量时点为0.761至0.901,支持效标效度;理论对应领域对的Spearman相关系数为0.289至0.716。
- QLU-C10D在15项已知组比较中检出9项差异,支持敏感性;所有QLU-C10D国家特定价值集均检出临床重要变化,支持反应性。
- QLU-C10D在74.7%的比较中统计效率高于EQ-5D-5L。
临床怎么用
- 作者推荐将QLU-C10D用于甲状腺癌治疗经济评价中的健康效用估计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Health economic appraisals often rely on the assessment of health utilities using preference-based measures (PBM). The cancer-specific PBM, European Organisation for Research and Treatment of Cancer Quality of Life Utility - Core 10 Dimensions (EORTC QLU-C10D), was developed recently, and now needs to be validated in various clinical populations. Methods: In a multicenter, multinational prospective cohort study, we longitudinally collected EORTC QLQ-C30 and EQ-5D-5L data from patients with thyroid cancer. We applied seven country-specific value sets to the QLQ-C30 data to derive country-specific utility values and used the EQ-5D-5L as a comparator PBM. Criterion validity was assessed by correlating index scores and Bland-Altman plots. Construct validity was investigated by correlating domain scores. Known-group comparisons and responsiveness were assessed using external clinical criteria. Results: A total of 181 patients with thyroid cancer from nine countries (three continents) provided analyzable data. Patients were included if they had differentiated, medullary, or anaplastic thyroid cancer. Mean utility values of both instruments were generally lower compared to general population norms. No floor or ceiling effects were present for the QLU-C10D. The intra-class correlation for EQ-5D-5L and QLU-C10D index values ranged from 0.761 to 0.901 across the measurement timepoints, supporting criterion validity. Spearman's correlation coefficients ranged from 0.289 to 0.716 for theoretically corresponding domain pairs. The QLU-C10D detected differences in 9 of 15 known-group comparisons, supporting sensitivity. Clinically important changes were detected by all QLU-C10D country specific value sets, supporting responsiveness. Further, the QLU-C10D had higher statistical efficiency than the EQ-5D-5L in 74.7% of comparisons. Conclusions: The QLU-C10D is a valid PBM for health economic evaluations in thyroid cancer studies. We recommend its use to estimate health utilities in economic evaluations of thyroid cancer therapies.
引用
- Pilz MJ, Seyringer S, Singer S, et al. The Cancer-Specific Health Economic Measure QLU-C10D is Valid and Responsive for Assessing Health Utility in Patients with Thyroid Cancer. Thyroid. 2024. PMID: 39475110. doi:10.1089/thy.2024.0396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。